MIRM
A biopharma name with actual momentum
Mirum Pharmaceuticals is doing the thing biotech companies always talk about and rarely pull off: turning a niche rare-disease focus into real revenue growth. In Q1 2026, the company said sales jumped 43% from a year earlier, which is the kind of number that makes investors sit up a little straighter.
That matters because Mirum isn’t playing the blockbuster-drug lottery. It’s trying to build a durable business around rare diseases with limited treatment options — the sort of market where execution matters more than hype. If you’re watching the stock, this is the kind of update that can support the “maybe this is a real business” narrative instead of the usual “please believe in the pipeline” pitch.
Why investors should keep an eye on it
For a biotech name, strong top-line growth can do a lot of heavy lifting. It can buy time, reduce some of the anxiety around funding, and make the market more forgiving if the next catalyst isn’t a moonshot.
What you’d want to watch next:
- whether growth stays this strong in the next quarter
- whether the company can keep expanding without torching cash
- whether the rare-disease portfolio keeps acting like a steady engine instead of a one-hit wonder
Big picture: Mirum is still in the “prove it” phase, but a 43% revenue jump is a pretty loud way to keep the conversation going.